Physician profile
Deborah D Dover
NPI 1972504850
$19,355.26
in general payments reported to CMS, 2019-2025
49 companies · $2,190 in 2025
The $2,190 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $1,533 · 2021: $589 · 2022: $1,351 · 2023: $1,188 · 2024: $2,440 · 2025: $2,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,349 · Travel and Lodging: $313 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,349.34 |
| Travel and Lodging | $312.67 |
| Education | $156.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $11,340.32 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $1,660.17 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Novartis Pharmaceuticals Corporation | $1,022.19 | 2019-2025 | |
| Medtronic, INC. | $741.30 | 2021-2024 | Percept PC Brainsense |
| Celgene Corporation | $542.88 | 2022-2025 | Zeposia |
| Biogen, INC. | $466.48 | 2020-2025 | Spinraza, Vumerity, Tysabri |
| Amgen INC. | $322.54 | 2019-2025 | Uplizna, Aimovig |
| Genzyme Corporation | $305.59 | 2019-2025 | |
| Ucb, INC. | $270.93 | 2019-2025 | Rystiggo, Zilbrysq, Briviact |
| Neurocrine Biosciences, INC. | $210.38 | 2019-2025 | Ingrezza, Ongentys |
| Emd Serono, INC. | $203.84 | 2022-2025 | Mavenclad, Mavenclad |
| Genentech USA, INC. | $191.28 | 2020-2025 | Evrysdi, Ocrevus Zunovo, Enspryng |
| Alexion Pharmaceuticals, INC. | $170.21 | 2019-2025 | Ultomiris |
| Amneal Pharmaceuticals LLC | $134.61 | 2022-2025 | Crexont, Rytary |
| Acadia Pharmaceuticals INC | $115.06 | 2019-2025 | Nuplazid |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Dover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.